Skip to main content
NCBI home page
British Medical Journal logoLink to British Medical Journal
. 1974 Apr 6;2(5909):7–10. doi: 10.1136/bmj.2.5909.7

Antioestrogens in Treatment of Breast Cancer: Value of Nafoxidine in 52 Advanced Cases

H J G Bloom, Evelyn Boesen
PMCID: PMC1610174  PMID: 4362455

Abstract

The synthetic non-steroidal antioestrogen nafoxidine (U-11, 100A) was given by mouth to 52 women with locally advanced or metastatic breast cancer, in 85% of whom the disease had become resistant to, or relapsed after, previous endocrine treatment. The objective response rate (complete or partial regression of disease) among 48 cases treated for at least four weeks was 37%. Tumours in soft tissue seemed to respond better than skeletal metastases. The patients in all but one of the 52 cases were postmenopausal. Those who had had an objective response to previous hormone treatment had a greater chance of deriving benefit from nafoxidine than those who had been resistant to hormone treatment.

Side effects of nafoxidine were dryness of skin, increased loss of scalp hair, and heightened sensitivity to sunlight. None were serious, and they could be lessened by protection from solar radiation or a decrease in dosage. No obvious depression of thyroid or adrenal function or obvious water retention or masculinization was seen. Cataract was a possible complication.

This clinical trial was preceded by laboratory studies in which a transplantable oestrogen-dependent tumour in the Syrian hamster was notably inhibited by the administration of nafoxidine. This experimental model may prove useful in screening potentially useful antioestrogenic agents against breast cancer before a human trial.

Full text

PDF
7

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bloom H. J., Roe F. J., Matchley B. C. Sex hormones and renal neoplasia. Inhibition of tumor of hamster kidney by an estrogen antagonist, an agent of possible therapeutic value in man. Cancer. 1967 Dec;20(12):2118–2124. doi: 10.1002/1097-0142(196712)20:12<2118::aid-cncr2820201209>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  2. Braunsberg H., James V. H., Irvine W. T., Jamieson C. W., James F., Sellwood R. A., Carter A. E., Hulbert M. Prognostic significance of oestrogen uptake by human breast-cancer tissue. Lancet. 1973 Jan 27;1(7796):163–165. doi: 10.1016/s0140-6736(73)90001-9. [DOI] [PubMed] [Google Scholar]
  3. Cole M. P., Jones C. T., Todd I. D. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer. 1971 Jun;25(2):270–275. doi: 10.1038/bjc.1971.33. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Engelsman E., Persijn J. P., Korsten C. B., Cleton F. J. Oestrogen receptor in human breast cancer tissue and response to endocrine therapy. Br Med J. 1973 Jun 30;2(5869):750–752. doi: 10.1136/bmj.2.5869.750. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. FOLCA P. J., GLASCOCK R. F., IRVINE W. T. Studies with tritium-labelled hexoestrol in advanced breast cancer. Comparison of tissue accumulation of hexoestrol with response to bilateral adrenalectomy and oophorectomy. Lancet. 1961 Oct 7;2(7206):796–798. doi: 10.1016/s0140-6736(61)91088-1. [DOI] [PubMed] [Google Scholar]
  6. Feherty P., Farrer-Brown G., Kellie A. E. Oestradiol receptors in carcinoma and benign disease of the breast: an in vitro assay. Br J Cancer. 1971 Dec;25(4):697–710. doi: 10.1038/bjc.1971.85. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hähnel R., Twaddle E., Vivian A. B. Estrogen receptors in human breast cancer. 2. In vitro binding of estradiol by benign and malignant tumors. Steroids. 1971 Dec;18(6):681–708. doi: 10.1016/0039-128x(71)90030-4. [DOI] [PubMed] [Google Scholar]
  8. Jones V., Joslin C. A., Jones R. E., Davies D. K., Roberts M. M., Gleave E. N., Campbell H., Forrest A. P. Progestagens and advanced breast cancer. Lancet. 1971 May 22;1(7708):1049–1050. doi: 10.1016/s0140-6736(71)91607-2. [DOI] [PubMed] [Google Scholar]
  9. Korenman S. G., Dukes B. A. Specific estrogen binding by the cytoplasm fof human breast carcinoma. J Clin Endocrinol Metab. 1970 May;30(5):639–645. doi: 10.1210/jcem-30-5-639. [DOI] [PubMed] [Google Scholar]
  10. Maass H., Engel B., Hohmeister H., Lehmann F., Trams G. Estrogen receptors in human breast cancer tissue. Am J Obstet Gynecol. 1972 Jun 1;113(3):377–382. doi: 10.1016/0002-9378(72)90688-6. [DOI] [PubMed] [Google Scholar]
  11. Sander S. In vitro uptake of oestradiol in DMBA induced breast tumours of the rat. Acta Pathol Microbiol Scand. 1969;75(4):520–526. [PubMed] [Google Scholar]
  12. Spaeren U., Olsnes S., Brennhovd I., Efskind J., Pihl A. Content of estrogen receptors in human breast cancer. Eur J Cancer. 1973 May;9(5):353–357. doi: 10.1016/0014-2964(73)90050-9. [DOI] [PubMed] [Google Scholar]
  13. Steggles A. W., King R. J. Oestrogen receptors in hamster tumours. Eur J Cancer. 1972 Jun;8(3):323–334. doi: 10.1016/0014-2964(72)90028-x. [DOI] [PubMed] [Google Scholar]
  14. Terenius L. Anti-oestrogens and breast cancer. Eur J Cancer. 1971 Feb;7(1):57–64. doi: 10.1016/0014-2964(71)90095-8. [DOI] [PubMed] [Google Scholar]
  15. Terenius L. Parallelism between oestrogen binding capacity and hormone responsiveness of mammary tumours in GR-A mice. Eur J Cancer. 1972 Feb;8(1):55–58. doi: 10.1016/0014-2964(72)90083-7. [DOI] [PubMed] [Google Scholar]
  16. Turner A. C., Barnes R. M., Green R. L. The effect of a preparation of vitamin A and calcium carbonate on sunburn. Practitioner. 1971 May;206(235):662–665. [PubMed] [Google Scholar]
  17. Ward H. W. Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. Br Med J. 1973 Jan 6;1(5844):13–14. doi: 10.1136/bmj.1.5844.13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Wittliff J. L., Hilf R., Brooks W. F., Jr, Savlov E. D., Hall T. C., Orlando R. A. Specific estrogen-binding capacity of the cytoplasmic receptor in normal and neoplastic breast tissues of humans. Cancer Res. 1972 Sep;32(9):1983–1992. [PubMed] [Google Scholar]

Articles from British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES